000 03358nam a22004695i 4500
001 978-3-7643-8989-5
003 DE-He213
005 20140220083819.0
007 cr nn 008mamaa
008 101029s2011 sz | s |||| 0|eng d
020 _a9783764389895
_9978-3-7643-8989-5
024 7 _a10.1007/978-3-7643-8989-5
_2doi
050 4 _aRB155-155.8
050 4 _aQH431
072 7 _aMFN
_2bicssc
072 7 _aMED107000
_2bisacsh
072 7 _aSCI029000
_2bisacsh
082 0 4 _a611.01816
_223
100 1 _aGasser, Susan M.
_eeditor.
245 1 0 _aEpigenetics and Disease
_h[electronic resource] :
_bPharmaceutical Opportunities /
_cedited by Susan M. Gasser, En Li.
264 1 _aBasel :
_bSpringer Basel :
_bImprint: Springer,
_c2011.
300 _aX, 270p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aProgress in Drug Research ;
_v67
505 0 _aDNA Methylation and Cancer -- Genome-wide Epigenetic Modifications in Cancer -- DNA Repair and the Control of DNA Methylation -- Errors in Erasure: Links Between Histone lysine Methylation Removal and Disease -- Histone Modifications in Cancer Biology and Prognosis -- Dynamics of Histone Lysine Methylation: Structures of Methyl Writers and Eraser -- Epigenetic Mechanisms of Mental Retardation -- Histone and DNA Modifications in Mental Retardation -- HDAC Inhibitors and Cancer Therapy -- Epigenetic Mechanisms in Acute Myeloid Leukemia -- The Liver-Specific MicroRNA miR-122: Biology and Therapeutic Potential -- Witold Filipowicz and Helge Großhans -- Transcriptional Regulatory Networks in Embryonic Stem Cells -- Small Molecules in Cellular Reprogramming and Differentiation.
520 _aEpigenetics has emerged recently as an important area of molecular biological studies. Epigenetic modifications lead to potentially heritable but reversible alterations in the expression of genes that determine cell fate. Epigenetic misregulation is thus often linked to degenerative diseases, cancer and neuronal disorders. Recent biomedical interest in this regulatory system stems from the fact that epigenetic, in contrast to genetic, alterations are in principle amenable to pharmacological intervention. A few epigenetically active drugs, for example histone deacetylase inhibitors (HDACi) and DNA methyltransferase (DNMT) inhibitors, have been approved by FDA for treatment of cancers such as CTCL, MDS, and AML. This volume explores the scientific background for clinical applications of epigenetically active drugs. Included are descriptions of epigenetic controls over gene expression, the post-transcriptional silencing of genes by RNA interference (RNAi) and microRNAs, as well as new findings from stem cell research which are relevant to pharmacological applications.
650 0 _aMedicine.
650 0 _aMedical genetics.
650 1 4 _aBiomedicine.
650 2 4 _aGene Function.
700 1 _aLi, En.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783764389888
830 0 _aProgress in Drug Research ;
_v67
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-7643-8989-5
912 _aZDB-2-SBL
999 _c108703
_d108703